Measure Up 2: A JAK Inhibitor's Numbers in Moderate-to-Severe Eczema

Atopic dermatitis — the chronic, intensely itchy inflammatory skin disease most people call eczema — gets dismissed as a cosmetic nuisance until you talk to someone living with the moderate-to-severe form. For them it is sleepless nights, raw and broken skin, and an itch that doesn't quit. The newest class of systemic treatments aims squarely at the inflammation driving it, and AbbVie's Measure Up 2 (NCT03607422), a Phase 3 trial of the oral JAK inhibitor upadacitinib, is one of the studies that defined how well that approach works. The registry record, now posted with full results, is a good place to see the trade-offs laid bare.

Upadacitinib is a small molecule that blocks Janus kinase 1, an enzyme that helps relay the inflammatory signals — including those from the cytokines IL-4 and IL-13 — that drive atopic dermatitis. Think of JAK1 as a switchboard operator inside the cell, passing along “inflame this tissue” messages; upadacitinib unplugs the operator. Because it's a pill rather than an injectable biologic, it's convenient, but blocking a signaling enzyme that the immune system uses broadly is also the source of its safety considerations. The trial was built to quantify both sides of that ledger.

The design

Measure Up 2 was a Phase 3 randomized, double-blind, placebo-controlled study — quadruple-masked, so participants, providers, investigators, and assessors were all blinded — enrolling 912 adolescents and adults aged 12 to 75 with moderate-to-severe atopic dermatitis who were candidates for systemic therapy. Participants were randomized to upadacitinib 15 mg once daily, upadacitinib 30 mg once daily, or placebo, taken orally for a 16-week double-blind period, after which the placebo group was re-randomized onto active drug and the study continued into a long blinded extension lasting up to 260 weeks. The two-dose design is important: it lets the data show whether more drug buys more benefit, and at what cost.

What the evidence shows

The trial had co-primary endpoints at week 16, both standard regulatory yardsticks for eczema. The first was EASI 75 — the proportion of patients achieving at least a 75% reduction in the Eczema Area and Severity Index, a composite of how much skin is affected and how badly. The second was a vIGA-AD score of 0 or 1 (clear or almost-clear skin) with at least a two-point improvement.

On EASI 75, placebo delivered a 13.3% response. Upadacitinib 15 mg reached 60.1%, and 30 mg reached 72.9%. On the stricter clear/almost-clear endpoint, placebo managed 4.7%, while the 15 mg and 30 mg arms hit 38.8% and 52.0% respectively. The dose-response is consistent and unambiguous: more drug, more clearance, on both measures. It is worth pausing on what the placebo numbers tell us. A 13.3% EASI 75 rate on placebo is low — and that low ceiling matters, because it means the active-drug responses are not being inflated by a population that improves easily on its own. The contrast is the evidence: when only one in eight untreated patients clears their skin by 75% but roughly three in four do on the high dose, the drug is plainly carrying that effect. And because atopic dermatitis is fundamentally a disease of itch, the pruritus data may matter most to patients — the proportion achieving a clinically meaningful four-point reduction in worst-itch score reached 41.9% on 15 mg and 59.6% on 30 mg, against 9.1% on placebo. The registry's secondary tables show this itch relief emerging early, within the first weeks of treatment.

The safety conversation oral JAK inhibitors require

Here is where the article has to slow down, because the efficacy numbers are only half the decision. During the 16-week double-blind period, the serious-adverse-event counts in the registry were broadly comparable across arms — for example, roughly 7 of 242 adults on placebo versus 3 to 7 per arm on active drug — which is reassuring over the short term. But the longer blinded extension period, where patients stayed on drug for up to five years, accumulates more serious events as any long-term exposure naturally does, and that is exactly the window regulators scrutinize for JAK inhibitors. The class carries boxed-warning concerns in many jurisdictions covering serious infections, blood clots, major cardiovascular events, and malignancy, drawn from the broader experience with JAK inhibition. None of that is unique to this trial, but the registry's extension-period tables are a reminder that an oral immunomodulator's risk profile is best read over years, not weeks.

This is also where the two-dose design earns its keep clinically. Because Measure Up 2 ran 15 mg and 30 mg side by side, it lets a prescriber and patient weigh the efficiency of escalation against its cost: the higher dose buys roughly thirteen more percentage points of EASI 75 response and a meaningfully better itch result, but a higher dose of a JAK inhibitor is also where dose-dependent safety signals tend to concentrate. The registry does not make that trade-off for the reader — it simply lays both doses' efficacy and adverse-event columns on the same page so the decision can be made on evidence rather than on a single number lifted from a summary.

Why this trial matters

Measure Up 2 quantifies a genuinely effective treatment for a disease that has historically been undertreated: roughly six to seven of ten patients reaching EASI 75 at the higher dose is a strong result against a placebo rate near one in eight, and the itch relief lands fast. But the registry's value is that it presents efficacy and the long-term safety tables in the same record, which is precisely how the upadacitinib decision should be made — dose against benefit against the monitoring its mechanism demands. The complete week-16 endpoint tables and the full adverse-event listings across both the double-blind and extension periods are available on the ClinicalTrials.gov study page.